- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02031861
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
February 3, 2015 updated by: Shanghai Shyndec Pharmaceutical Co., Ltd.
Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat)in the treatment of mild to moderate essential hypertension.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Voluntarily participate and must sign informed consent form
- Mild to moderate essential hypertension (SBP 140-179 mmHg and/or DBP 90-109 mmHg)
- Average DBP measured by 24-hour ambulatory blood pressure monitoring (ABPM) ≥80 mmHg
Exclusion Criteria:
- Secondary hypertension and malignant hypertension
- Pregnant or nursing women, or patients that cannot guarantee to take effective contraception measures
- Baseline SBP≥180 mmHg or DBP≥110 mmHg, or patients with cerebral, cardiac or renal complications
- Have following complications: cerebrovascular accident within 6 months, myocardial infarction or cardiac failure, macroaneurysm or dissecting aneurysm, definite angina, A-V block of grade 2 or higher, sick sinus syndrome, atrial fibrillation or other malignant arrhythmia
- Clinical significant diseases of heart, lung, liver, kidney and hematologic system or malignant tumors, HIV infection, uncontrolled diabetes (fasting blood glucose ≥7.0 mmol/L, 2-hour postprandial blood glucose ≥7.8 mmol/L)
- Kock pouch
- Sever gastrointestinal stenosis
- Abnormal laboratory values with clinical significance, including serum potassium <3.5 or >5.5 mmol/L, glutamic-pyruvic transaminase (ALT) or glutamic oxalacetic transaminase (AST) >2-fold upper limit of normal (ULN), Cr >ULN
- Uric acid >ULN with the diagnosis of gout
- Gastrointestinal abnormalities or surgery that may interfere with drug absorption
- Hyperthyroidism or hypothyroidism
- Allergic to any ingredient or metabolite of investigational drug or drugs of similar structure
- Heavy smokers (>25 cigarettes every day), alcoholics (>250 ml liquor every day), drug addicts
- Psychological diseases, acrasia, cannot express explicitly
- Patients whose mood may be affected by variations in blood pressure, which in turn increases blood pressure
- Anxiety disorders, depression or cannot follow study protocol
- BMI >30
- Night shift, irregular sleep patterns or insomnia
- participate in other clinical trials within 3 months
- other conditions that investigators consider unsuitable for participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: nifedipine CR tablets (Xin Ran)
Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
|
|
ACTIVE_COMPARATOR: nifedipine CR tablets (Adalat)
Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in morning blood pressure surge from baseline
Time Frame: 12 weeks
|
12 weeks
|
change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in morning blood pressure from baseline
Time Frame: 12 weeks
|
12 weeks
|
T/P ratio
Time Frame: 12 weeks
|
12 weeks
|
average reduction in systolic blood pressure from 18 to 24 hours after administration
Time Frame: 12 weeks
|
12 weeks
|
average reduction in diastolic blood pressure from 18 to 24 hours after administration
Time Frame: 12 weeks
|
12 weeks
|
smoothness index
Time Frame: 12 weeks
|
12 weeks
|
change in morning blood pressure surge from baseline
Time Frame: 8 weeks
|
8 weeks
|
change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline
Time Frame: 8 weeks
|
8 weeks
|
change in morning blood pressure from baseline
Time Frame: 8 weeks
|
8 weeks
|
T/P ratio
Time Frame: 8 weeks
|
8 weeks
|
average reduction in systolic blood pressure from 18 to 24 hours after administration
Time Frame: 8 weeks
|
8 weeks
|
average reduction in diastolic blood pressure from 18 to 24 hours after administration
Time Frame: 8 weeks
|
8 weeks
|
smoothness index
Time Frame: 8 weeks
|
8 weeks
|
change in systolic blood pressure (SBP) from baseline
Time Frame: 12 weeks
|
12 weeks
|
change in diastolic blood pressure (DBP) from baseline
Time Frame: 12 weeks
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical laboratory test and adverse event
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Pingjin Gao, Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (ACTUAL)
July 1, 2014
Study Completion (ACTUAL)
July 1, 2014
Study Registration Dates
First Submitted
January 8, 2014
First Submitted That Met QC Criteria
January 8, 2014
First Posted (ESTIMATE)
January 9, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
February 5, 2015
Last Update Submitted That Met QC Criteria
February 3, 2015
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Essential Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Nifedipine
Other Study ID Numbers
- CH-004PIV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Hypertension
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on nifedipine CR tablets (Xin Ran)
-
Shanghai Shyndec Pharmaceutical Co., Ltd.Unknown
-
Cao YuUnknownTherapeutic EquivalencyChina
-
BayerCompleted
-
Actavis Inc.Completed
-
Center for Clinical Pharmacology Research Bdbeq...Completed
-
Actavis Inc.Completed
-
The Third Xiangya Hospital of Central South UniversityUnknown